Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Phase I/II, Open-labeled, Prospective, Multi-center study of a Pretargeted Radioimmunotherapy
in metastatic colorectal cancer with ractionated injections of TF2 plus 90Y-IMP288
(RITCOLON).